CD47 and neoplasm: Here, we hypothesized that simultaneously targeting PD-L1 and CD47 on tumor-infiltrating Treg cells could result in their depletion, metabolic reprogramming, and enhanced antitumor immunity—while reducing off-tumor toxicity.